pancreatic cancer
The firm recently started treating patients in a Phase I trial of its pol theta helicase inhibitor and filed an IND for its Werner helicase-targeted drug candidate.
Foundation Medicine, Merus to Develop CDx for Cancer Drug to Treat Patients With NRG1 Fusions
The companies will use Foundation's RNA sequencing platform to develop a companion diagnostic for Merus' bispecific antibody zenocutuzumab.
Diakonos Oncology Closes Oversubscribed $11.4M Seed Financing Round
The investment will fund operations through late 2025, including a readout from a Phase I trial of the firm's personalized cancer vaccine in glioblastoma.
The firm expects to begin Phase I trials of mesothelin-targeted ZW171 and FRα-targeted ZW191 in the coming months in difficult-to-treat cancers.
MOMA Therapeutics Launches Phase I Trial of Polymerase Theta Inhibitor
The firm is initially evaluating MOMA-313 with a PARP inhibitor in homologous recombination-deficient advanced solid tumors.
Mar 21, 2024
Feb 14, 2024
Nov 29, 2023